section name header

Pronunciation

lee-voe-mil-NA-si-pran

Classifications

Therapeutic Classification: antidepressants

Pharmacologic Classification: selective serotonin and norepinephrine reuptake inhibitors-SSNRIs

Indications

BEERS REMS


Action

  • Inhibits neuronal reuptake of norepinephrine and serotonin in the CNS.
Therapeutic effects:
  • Decrease in depressive symptomatology, with fewer relapses/recurrences.

Pharmacokinetics

Absorption: Well absorbed (92%) following oral administration.

Distribution: Widely distributed.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP3A4 isoenzyme. 58% eliminated unchanged in urine; 42% metabolized; metabolites are renally eliminated.

Half-Life: 12 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown6–8 hrunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypertension, hypotension, palpitations, tachycardia

Derm: hot flushes, hyperhidrosis, rash

EENT: mydriasis

Endo: SIADH

F and E: hyponatremia

GI: nausea, appetite, constipation, vomiting

GU: libido, delayed/absent orgasm, ejaculatory delay/failure, erectile dysfunction, testicular pain, urinary hesitation/retention

Hemat: BLEEDING

Neuro: activation of mania/hypomania, SUICIDAL THOUGHTS/BEHAVIORS

Misc: SEROTONIN SYNDROME

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Fetzima